Genentech Avastin Label Adds Third-Line Data Showing Minimal Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
NCI study of bevacizumab demonstrated a 1% response rate in refractory metastatic colorectal cancer when combined with 5-FU/LV.
You may also be interested in...
Genentech Files Avastin sBLA For Relapsed Metastatic Colorectal Cancer
The application would expand on an October labeling change which added third-line data.
Genentech Files Avastin sBLA For Relapsed Metastatic Colorectal Cancer
The application would expand on an October labeling change which added third-line data.
Genentech Halts Avastin Trial Enrollment Due To GI Perforations
Phase II study of bevacizumab in platinum-refractory ovarian cancer patients demonstrated a higher rate of GI perforations than previously seen in studies of the oncologic.